SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
152 hedge funds and large institutions have $137M invested in SANGAMO THERAPEUTICS INC in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 48 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 43
4.95% less ownership
Funds ownership: 66.6% → 61.65% (-5%)
15% less funds holding
Funds holding: 179 → 152 (-27)
30% less capital invested
Capital invested by funds: $198M → $137M (-$60.1M)
48% less call options, than puts
Call options by funds: $85K | Put options by funds: $162K
56% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$4.66M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.22M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.72M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$1.06M |
| 5 |
GC
Globeflex Capital
San Diego,
California
|
+$953K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.61M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.35M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.71M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.41M |
| 5 |
Rafferty Asset Management
New York
|
-$1.16M |
SGMO Hedge Fund Activity: Q2 2023 in Review
152 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q2 2023, worth a combined $137M — down 30% from $198M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of SGMO and 21 opened new positions — a net loss of 27 holders — while 43 trimmed existing stakes and 47 added.
The largest buyer was Wasatch Advisors, adding an estimated $4.66M. The largest seller was State Street, cutting an estimated $8.61M.
- 152 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q2 2023, down from 179 in Q1 2023.
- Funds reported $137M of SANGAMO THERAPEUTICS INC stock for Q2 2023, down 30% quarter-over-quarter.
- 21 funds opened new SANGAMO THERAPEUTICS INC positions in Q2 2023 and 48 closed out, a net change of -27 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q2 2023 was Wasatch Advisors, an estimated $4.66M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q2 2023 was State Street, an estimated $8.61M sold.
Based on aggregated 13F filings for Q2 2023.